The historical rank and industry rank for Glenmark Pharmaceuticals's Net Margin % or its related term are showing as below:
NSE:GLENMARK'
s Net Margin % Range Over the Past 10 Years
Min: -12.91 Med: 8.06 Max: 10.33
Current: 8.15
NSE:GLENMARK's Net Margin % is ranked better than 58.13% of 953
companies
in the Drug Manufacturers industry
Industry Median: 5.69
vs NSE:GLENMARK: 8.15
Glenmark Pharmaceuticals (NSE:GLENMARK) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Glenmark Pharmaceuticals Net Margin % Related Terms
Glenmark Pharmaceuticals Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:GLENMARK vs ZTS, UTHR: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Glenmark Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Glenmark Pharmaceuticals Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Glenmark Pharmaceuticals's Net Margin % distribution charts can be found below:
* The bar in red indicates where Glenmark Pharmaceuticals's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Glenmark Pharmaceuticals (NSE:GLENMARK) has a Net Margin % of 8.02% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Glenmark Pharmaceuticals and its competitors. This is near median its historical median of 8.06. According to the industry distribution chart, Glenmark Pharmaceuticals ranks #399 out of 953 companies in the Drug Manufacturers industry, placing it in the top 41.9%.
Is Glenmark Pharmaceuticals' Net Margin % too high?
Glenmark Pharmaceuticals' current Net Margin % of 8.02% is near median its 10-year median of 8.06. The Drug Manufacturers industry median Net Margin % is 5.69. Glenmark Pharmaceuticals' value of 8.02% is 40.9% above this industry median. Based on the distribution chart, Glenmark Pharmaceuticals ranks #399 out of 953 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Glenmark Pharmaceuticals has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Glenmark Pharmaceuticals' Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Glenmark Pharmaceuticals ranks #399 out of 953 companies for Net Margin %. This puts Glenmark Pharmaceuticals in the upper half of its industry. The industry median Net Margin % is 5.69. Glenmark Pharmaceuticals' value of 8.02% is 40.9% above this benchmark. While the company's 10-year median is 8.06 vs. the industry median of 5.69, Glenmark Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.69, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Glenmark Pharmaceuticals's current Net Margin % of 8.02% is 40.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Glenmark Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Glenmark Pharmaceuticals's current Net Margin % is 8.02%, which is near median its own 10-year median of 8.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glenmark Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Glenmark Pharmaceuticals (NSE:GLENMARK) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,988.54, compared to a current price of ₹2,186.60 — trading 10% above its estimated fair value. The current Net Margin % is 8.02%, which is near median its 10-year median of 8.06 and 40.9% above the Drug Manufacturers industry median of 5.69. Glenmark Pharmaceuticals' overall GF Score™ is 86/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Glenmark Pharmaceuticals (NSE:GLENMARK), the current Net Margin % is 8.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Glenmark Pharmaceuticals (NSE:GLENMARK) Overvalued in 2026?
Based on GuruFocus' analysis, Glenmark Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹2,186.60 is trading 10% above its estimated GF Value™ of ₹1,988.54.
GuruFocus considers Glenmark Pharmaceuticals to be Fairly Valued.
Key valuation signals for NSE:GLENMARK:
Net Margin %: 8.02% (near median its 10-year median of 8.06)
GF Value™: ₹1,988.54 vs. price of ₹2,186.60 (10% above fair value)
Industry Position: 40.9% above the Drug Manufacturers median (#399 of 953)
No single metric tells the full story. See the NSE:GLENMARK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities. It has a business presence in different therapeutic areas such as dermatology, respiratory, oncology, diabetes, cardiovascular, and oral contraceptives among others. Geographically, it derives key revenue from India and the rest from North America, Latin America, Europe and the Rest of the world.
86GF Score
Get the complete analysis for NSE:GLENMARK
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLENMARK has been successfully added to your 
